2020
Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients
Deig C, Trone K, Beneville B, Stratton A, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Attia F, Bassale S, Chen Y, Keith D, Chen E, Lopez C, Gilbert E, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e581-e582. DOI: 10.1016/j.ijrobp.2020.07.1786.Peer-Reviewed Original ResearchPerioperative complication rates following neoadjuvant therapy in pancreatic adenocarcinoma.
Deig C, Beneville B, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Gilbert E, Lopez C, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Perioperative complication rates following neoadjuvant therapy in pancreatic adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 688-688. DOI: 10.1200/jco.2020.38.4_suppl.688.Peer-Reviewed Original ResearchPerioperative complication rateNeoadjuvant therapyComplication ratePancreatic adenocarcinomaNeo-CRTUpfront resectionUpfront surgeryHospital lengthExact testComparable perioperative complication ratesSignificant differencesAcademic tertiary referral centerInstitutional cancer registryMedian hospital lengthNeoadjuvant radiation therapyPatients Undergoing ResectionTotal neoadjuvant therapyPost-operative mortalityTertiary referral centerResectable pancreatic adenocarcinomaAdditional surgical riskFisher's exact testT-testStudent's t-testUndergoing resection
2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3